Search for a trial

A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN*S DISEASE

The primary objective of the study is to assess the safety and tolerability of long-term open-label CP-690,550 therapy in subjects with CD.Secondary objectives are to evaluate the effect of CP-690,550 maintenance therapy on clinical remission and on…

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

Cohort 1:A data monitoring committee (DMC) will evaluate all available safety data from the study. The first 2 meetings for safety surveillance will occur after 50 and 100 subjects complete or discontinue from the Blinded Induction Phase from Cohort…

Human intestinal ischemia and reperfusion

This study aims at (further) revealing the pathophysiology of intestinal IR in man, with a specific interest for the role of proteases and protease-activated receptor-2 (PAR-2), cellular and inflammatory changes, barrier function and intestinal…

A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)

The primary objective of this study is to evaluate the tumor response of stable disease (SD), partial response, or complete response at at 12 weeks (according to RECIST 1.1 criteria) in two separate cohorts representing molecularly distinct subsets…

A phase IIb, Double Blind, Randomized, placebo- controlled, Double-Dummy, Dose Rangining Study To Evaluate the Clinical Efficacy and Safety of Induction and Maintenance therapy with BMS- 945429 in subjects with Moderate to Severe Crohn's Disease.

Objectives1.3.1 Primary ObjectiveCompare the efficacy of BMS-945429 versus placebo for induction of clinical remission (defined by an absolute Crohn*s Disease Activity Index [CDAI] score < 150) at Week 8 (IP-57).1.3.2 Secondary Objectives•…

Pre-operative Administration of Anti-EGFR Monoclonal Antibodies (cetuximab) for the Eradication of Circulating Tumor Cells in Patients Undergoing Curative Treatment of Colorectal Liver Metastases; a dose finding study

The main objective of this study is to determine whether a single neoadjuvant gift of anti-EGFR mAb, administered 48 hours prior to local treatment of colorectal liver metastases, reduces the number of CTCs. Secondary endpoints are determination of…

Inhibition of salivary glands to reduce uptake of radioactive Iodine

Primary: to determine if inhibition with GPB can provide a significant (>30%) reduction in the accumulation of orally administered Iodine-123 in salivary glands, measured at 4h after administraion. Secondary: to determine if a reduction at 4h…

Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study

This study has been transitioned to CTIS with ID 2024-513635-24-00 check the CTIS register for the current data. The aim of the study is to investigate the effectiveness and safety of the new drug nivolumab for the treatment of esophageal cancer. In…

A phase 2 intervention study:
Detection of early esophageal neopastic lesions by quantified fluorescence molecular endoscopy using oral and topical administration of bevacizumab-800CW and cetuximab-800CW

Primary objectives:The primary objectives are to evaluate the feasibility of oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE to shorten the qFME procedure and test whether…

A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe ulcerative colitis; CALDOSE-1

To determine the optimal dose of IMU-838 to induce symptomatic remission and endoscopic healing in patients with moderate-to-severe ulcerative colitis (UC)

Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advanced or recurrent rectal cancer patients undergoing curative surgery.

This study has been transitioned to CTIS with ID 2024-510768-21-00 check the CTIS register for the current data. This study aims to investigate if fluorescence guided surgery performed with SGM-101 can improve R0 resection rates and allows to find…

A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

This study has been transitioned to CTIS with ID 2023-506046-24-00 check the CTIS register for the current data. Main:To evaluate the long-term safety and tolerability of efavaleukin alfa in subjects with moderate to severe ulcerative colitis (UC)…

A performance study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for fluorescence-guided imaging to determine local extent and resectability during surgical resection of pancreatic ductal adenocarcinoma after neoadjuvant treatment

This study has been transitioned to CTIS with ID 2023-510481-27-00 check the CTIS register for the current data. This study evaluates the yield of NIR-Fluorescence imaging as additional surgical-tool for visualization and assessment of local extent…